FURTHER OBSERVATIONS ON THE IMMUNOLOGICAL BEHAVIOUR OF HUMAN PITUITARY AND CHORIONIC GONADOTROPHINS

1964 ◽  
Vol 29 (3) ◽  
pp. 263-271 ◽  
Author(s):  
G. ILLEI ◽  
PAMELA M. MORITZ

SUMMARY Antisera were raised to human chorionic gonadotrophin (HCG) and human menopausal gonadotrophin (HMG). Normal human serum and human pituitary and chorionic gonadotrophins reacted with both antisera in immunological experiments. After absorption with human serum, the γ-globulin fractions of the antisera were isolated, and only the reaction to the hormone preparations remained. Immunoelectrophoresis revealed a common antigenic factor in the α2-β globulin region. The γ-globulin fraction of HCG antiserum seems to be suitable for the assay of HCG, while that of the HMG antiserum might be employed for the detection of HMG.

1966 ◽  
Vol 53 (3) ◽  
pp. 420-428 ◽  
Author(s):  
C. Robyn ◽  
P. O. Hubinont ◽  
E. Diczfalusy

ABSTRACT Immunologically mono-specific antisera prepared against human chorionic gonadotrophin (HCG) preparations completely neutralized in vitro as well as in vivo the luteinizing hormone (LH) and also the follicle-stimulating hormone (FSH) activity of both human hypophyseal gonadotrophin (HHG) and human menopausal gonadotrophin (HMG) preparations.


1968 ◽  
Vol 59 (2) ◽  
pp. 277-297 ◽  
Author(s):  
C. Robyn ◽  
E. Diczfalusy

ABSTRACT Methods are described for the bioassay of the human follicle stimulating hormone (FSH) neutralising potency of antigonadotrophic sera. The methods are based on a modified ovarian weight augmentation test using human chorionic gonadotrophin (HCG) or luteinising hormone (LH) of ovine origin for augmentation. The antigonadotrophic sera were obtained following immunisation of rabbits with HCG, human menopausal gonadotrophin (HMG) and human hypophysial gonadotrophin (HHG) preparations. The FSH neutralising potencies of these antisera were assayed against laboratory standard preparations of HMG and HHG and against the Second International Reference Preparation of HMG. When HCG was used for augmentation, the FSH neutralising potency of antisera depended on the sequence in which HCG, HMG and antiserum were combined. When HCG was mixed with the antiserum prior to the addition of HMG, this resulted in a significant decrease in the FSH neutralising potency. When HCG was injected separately from the HMG-antiserum complex, the FSH neutralising potency increased. However, the FSH neutralising potency of all antisera was significantly higher when LH of ovine origin, rather than HCG was used for augmentation. Anti-HCG sera exhibited a considerable FSH neutralising potency, even when prepared by immunisation with HCG preparations of high specific activity. These high FSH neutralising potencies were in contrast to the low FSH activity of the HCG preparations used for immunisation. Anti-HMG sera possessed little, if any, FSH neutralising potency. These poor FSH neutralising potencies were in contrast to the high FSH activity of the HMG preparations used for immunisation. The FSH neutralising potency of an anti-HHG serum was at least 5 times higher when assayed against HMG, than when assayed against HHG. The data presented indicate that HCG preparations extensively compete with FSH preparations for antibodies neutralising FSH activity. This suggests that there is a cross reaction between HCG and FSH. The data also indicate, that there are significant differences in the antigenic properties of human pituitary and urinary gonadotrophins. It is concluded, that the establishment of specificity of immunoassay methods for human gonadotrophins cannot be based exclusively on immunological evidence. Also, the absorption procedures used to improve the specificity of antigens and antisera are of limited value, unless carried out in a strictly quantitative manner following the establishment of the profile of the gonadotrophic and antigonadotrophic activities present.


1982 ◽  
Vol 31 (3-4) ◽  
pp. 247-253 ◽  
Author(s):  
John A. Lamont

A literature review of the occurrence of multiple pregnancies associated with artificial induction of ovulation is reported. This report considers three treatment schedules: (1) clomiphene citrate; (2) human pituitary gonadotrophin with human chorionic gonadotrophin; and (3) human menopausal gonadotrophin with human chorionic gonadotrophin. The majority of the increase in twinning is related to hyperstimulation of the ovary by these medications, resulting in dizygotic twinning. The true incidence of twin pregnancy cannot be calculated because the vital statistics of all nations report live birth rates. Increased rates of fetal wastage, late abortion and prematurity associated with the occurrence of multiple pregnancies are overlooked by these statistics. The increased incidence of twinning appears to be related to the type and dosage of medication used, and the patient's underlying problem.


1967 ◽  
Vol 56 (4) ◽  
pp. 649-660 ◽  
Author(s):  
Olav Trygstad ◽  
Irene Foss

ABSTRACT A lipid-mobilizing factor (LMF) has previously been prepared from human pituitary glands. The LMF was strongly adipokinetic in rabbits. Subcutaneous injection of 0.1 mg gave an increase of serum nonesterified fatty acids (NEFA) in the range of 5 meq./l. Addition of 3 ml normal human serum to LMF reduced its adipokinetic effect. The inhibition of LMF by human serum was specific, since serum from mouse or pig did not reduce the increase of serum NEFA induced by LMF, and human serum had no influence on the adipokinesis given by whale, pig, or synthetic ACTH preparations in rabbits. The human serum inhibition of LMF was located to the gamma G globulin fraction by DEAE-cellulose chromatography. Serum from six children with generalized lipodystrophy had a negligible influence on the adipokinesis in rabbits induced by LMF. Sera from one group of obese patients reduced the adipokinetic effect of LMF as normal control sera, while sera from another group of obese patients made the increase of serum NEFA negligible. It is suggested that the first group of obese patients may be related to Mayer's simple regulatory or 'hyperphagic' type of obesity and the latter to his metabolic type of obesity. Furthermore possible mechanisms for the human serum inhibition of LMF are discussed.


1972 ◽  
Vol 71 (3) ◽  
pp. 443-453 ◽  
Author(s):  
Olav Trygstad ◽  
Irene Foss

ABSTRACT A lipid-mobilizing factor (LMF) with an adipotrophic effect in human and animal fat tissue has been prepared from human pituitary glands. The addition of normal human serum to LMF reduced its lipolytic effect, and it was completely abolished by serum from a group of obese patients, whereas the lipolysis was not influenced by serum from patients with generalized lipodystrophy. By DEAE-cellulose chromatography of human serum the inhibitory effect on LMF was found to be present in a protein fraction less acidic than the main serum albumin fraction. The inhibitory fraction was deprived of some contaminants by Sephadex gel filtration. Disc electrophoresis demonstrated the presence of three components in the inhibitory protein (IP), and they were identified as albumin, transferin, and haemopexin by immuno-electrophoresis. Precipitation of these proteins by their rabbit antisera demonstrated that the inhibitory effect was present in the albumin fraction. Insulin like activity was not observed in IP. A protein binding of LMF by IP could not be demonstrated. Incubation at 37°C for one hour of a mixture of LMF and IP eliminated the electrophoretic picture of LMF. It is concluded that the inhibitory effect of human serum may be due to proteolysis of LMF.


1982 ◽  
Vol 28 (1) ◽  
pp. 119-121 ◽  
Author(s):  
E Piall ◽  
G W Aherne ◽  
V Marks

Abstract We evaluated a commercially available (Diagnostic Biochemistry Inc.) doxorubicin 125I radioimmunoassay kit. This kit gave a high apparent doxorubicin concentration (greater than 12 micrograms/L), which was not linearly related to dilution, for two pools of normal human serum and plasma and also for samples collected from patients before they received the drug. In contrast, a doxorubicin 3H radioimmunoassay developed by us gave a low blank (2 micrograms/L), which was linearly related to dilution, for the same pools and patients' samples. Doxorubicin concentrations in the plasma of patients receiving the drug were compared by the two methods; the kit gave results five- to 10-fold those obtained with our assay. High nonspecific interference by serum and plasma as measured by the 125I radioimmunoassay must therefore be borne in mind by users of the kit, and we suggest that results should be corrected for these nonspecific effects.


Sign in / Sign up

Export Citation Format

Share Document